8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine has been researched along with n(6)-cyclopentyladenosine in 5 studies
| Studies (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Trials (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Recent Studies (post-2010) (8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine) | Studies (n(6)-cyclopentyladenosine) | Trials (n(6)-cyclopentyladenosine) | Recent Studies (post-2010) (n(6)-cyclopentyladenosine) |
|---|---|---|---|---|---|
| 28 | 0 | 12 | 605 | 0 | 62 |
| Protein | Taxonomy | 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine (IC50) | n(6)-cyclopentyladenosine (IC50) |
|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.2256 | |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | 1.16 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0027 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 1.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beukers, MW; de Groote, M; IJzerman, AP; Menge, WM; Timmerman, H; van de Stolpe, AC; van der Graaf, PH; van der Sluis, RP; van Muijlwijk-Koezen, JE | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Baker, SP; Belardinelli, L; Scammells, PJ | 1 |
| Gesztelyi, R; Haines, DD; Juhasz, B; Kiss, Z; Pak, K; Szentmiklosi, AJ; Tosaki, A; Varga, B; Zsuga, J | 1 |
5 other study(ies) available for 8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine and n(6)-cyclopentyladenosine
| Article | Year |
|---|---|
Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a 'receptor knock-down' tool.
Topics: Animals; Binding Sites; Cyclic AMP; Heart Rate; In Vitro Techniques; Purinergic P1 Receptor Antagonists; Rats; Xanthines | 2001 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells.
Topics: Adenosine; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Muscle, Smooth; Receptors, Purinergic P1; Xanthines | 2000 |
The guinea pig atrial A1 adenosine receptor reserve for the direct negative inotropic effect of adenosine.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Animals; Atrial Function; Dose-Response Relationship, Drug; Guinea Pigs; Heart Atria; In Vitro Techniques; Male; Myocardial Contraction; Receptor, Adenosine A1; Thioinosine; Xanthines | 2013 |